This study evaluated the survival benefits of repeated removal of lung metastases in patients with colorectal cancer. Additionally, the authors aimed to identify which patients would benefit the most from this treatment. 

This study explored whether cetuximab (erbitux) can benefit patients with unresectable colorectal liver metastases. The ability to perform surgery to remove part or all of the tumor growth in the liver (the resection rate) was compared between patients receiving cetuximab in combination with chemotherapy, to those receiving chemotherapy alone.

This study evaluated the frequency and severity of nerve damage (neuropathy) caused by chemotherapy in patients with colorectal cancer. Additionally, researchers evaluated the impact this side effect has on patients’ quality of life.

This article reviewed the use of anti-inflammatory medications as treatment for colorectal cancer.

This article evaluated the effects of chemotherapy after the surgical removal of liver and lung metastases on survival in patients with colorectal cancer (CRC). 

This review evaluated the association between body mass index (BMI) and survival in patients with colorectal cancer (CRC). 

This report aimed to establish if radiofrequency ablation (RFA) of liver metastases originating from colorectal cancer (CRC) provides any benefits to patients with Stage IV of the disease. Main result: RFA extends progression-free survival by 7 months.

Cancer that begins in the colon is called colon cancer, and cancer that begins in the rectum is called rectal cancer. Cancers affecting either of these organs also may be called colorectal cancer. These two organs form the final part of the digestive system (see photo).

Colorectal cancer occurs when some of the cells that line the colon or the rectum become abnormal and grow out of control. The abnormally growing cells create a tumor, which is the cancer.